Ten-year supra-network experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis

Kelechi Njoku(Leeds Teaching Hospitals NHS Trust), Alison Tree(Royal Marsden NHS Foundation Trust), Angus Robinson(Royal Sussex County Hospital), Maria Aparecida Alves de Oliveira Serra(Institute of Cancer Research), Lisa Pickering(Royal Marsden Hospital), S. Beesley(Maidstone Hospital), Lona Vyas(Leeds Teaching Hospitals NHS Trust), Mehran Afshar(Iran University of Medical Sciences), Oliver Kayes(University of Leeds), Benjamin Ayres, Michael Ager(St George's Hospital), Ann Henry(University of Leeds), M. Elmamoun(Leeds Teaching Hospitals NHS Trust), Ian Eardley(Leeds Teaching Hospitals NHS Trust), Nick Watkin, Perric Crellin
Clinical Oncology
October 1, 2019
10.1016/j.clon.2019.09.062
Cited by 0

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
|Cell|2018|883
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
|Cancer Cell|2018|591